AU2019252285B2 - Viral vectors and packaging cell lines - Google Patents

Viral vectors and packaging cell lines Download PDF

Info

Publication number
AU2019252285B2
AU2019252285B2 AU2019252285A AU2019252285A AU2019252285B2 AU 2019252285 B2 AU2019252285 B2 AU 2019252285B2 AU 2019252285 A AU2019252285 A AU 2019252285A AU 2019252285 A AU2019252285 A AU 2019252285A AU 2019252285 B2 AU2019252285 B2 AU 2019252285B2
Authority
AU
Australia
Prior art keywords
lentiviral
cell
domain
cells
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019252285A
Other languages
English (en)
Other versions
AU2019252285A1 (en
Inventor
Laurie BEITZ
Andrew Scharenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umoja Biopharma Inc
Original Assignee
Umoja Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umoja Biopharma Inc filed Critical Umoja Biopharma Inc
Publication of AU2019252285A1 publication Critical patent/AU2019252285A1/en
Application granted granted Critical
Publication of AU2019252285B2 publication Critical patent/AU2019252285B2/en
Priority to AU2025237995A priority Critical patent/AU2025237995A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019252285A 2018-04-12 2019-04-11 Viral vectors and packaging cell lines Active AU2019252285B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025237995A AU2025237995A1 (en) 2018-04-12 2025-09-25 Viral vectors and packaging cell lines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656823P 2018-04-12 2018-04-12
US62/656,823 2018-04-12
PCT/US2019/026923 WO2019200056A2 (en) 2018-04-12 2019-04-11 Viral vectors and packaging cell lines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025237995A Division AU2025237995A1 (en) 2018-04-12 2025-09-25 Viral vectors and packaging cell lines

Publications (2)

Publication Number Publication Date
AU2019252285A1 AU2019252285A1 (en) 2020-10-29
AU2019252285B2 true AU2019252285B2 (en) 2025-06-26

Family

ID=66287035

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019252285A Active AU2019252285B2 (en) 2018-04-12 2019-04-11 Viral vectors and packaging cell lines
AU2025237995A Pending AU2025237995A1 (en) 2018-04-12 2025-09-25 Viral vectors and packaging cell lines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025237995A Pending AU2025237995A1 (en) 2018-04-12 2025-09-25 Viral vectors and packaging cell lines

Country Status (10)

Country Link
US (3) US12215337B2 (OSRAM)
EP (1) EP3775231A2 (OSRAM)
JP (2) JP7721436B2 (OSRAM)
CN (1) CN112262214A (OSRAM)
AU (2) AU2019252285B2 (OSRAM)
BR (1) BR112020020887A2 (OSRAM)
CA (1) CA3096458A1 (OSRAM)
IL (2) IL327388A (OSRAM)
SG (1) SG11202009975TA (OSRAM)
WO (1) WO2019200056A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
WO2020106992A1 (en) 2018-11-21 2020-05-28 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
CA3154281A1 (en) * 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
CN115697388A (zh) * 2020-01-30 2023-02-03 优莫佳生物制药股份有限公司 双特异性转导增强子
US20230201440A1 (en) * 2020-05-08 2023-06-29 Innovative Cellular Therapeutics Holdings, Ltd. System and method for gene and/or cellular therapy
JP2023551220A (ja) * 2020-11-20 2023-12-07 ウモジャ バイオファーマ インコーポレイテッド 複数のポリヌクレオチドを送達するためのベクター系およびその使用法
MX2023008831A (es) 2021-01-27 2023-10-19 Umoja Biopharma Inc Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
AU2023265993A1 (en) * 2022-05-06 2024-10-31 Umoja Biopharma, Inc. Viral particle with surface stimulating molecules
KR20250121163A (ko) * 2022-11-04 2025-08-11 우모자 바이오파마 인코포레이티드 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
WO2024097992A2 (en) * 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
KR20260005358A (ko) 2023-04-27 2026-01-09 밀테니 비오텍 비.브이. & 씨오. 케이지 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자
WO2024238153A1 (en) * 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2024238769A2 (en) * 2023-05-16 2024-11-21 The Regents Of The University Of California Inhibitory chimeric antigen receptors that reduce car-t cell "on-target, off-tumor" toxicity
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP0981636B1 (en) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2002538842A (ja) 1999-03-16 2002-11-19 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 大量のスクリーニングのためのレンチウイルスベクター系
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US7135339B2 (en) 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
EP1769078A1 (en) 2004-07-01 2007-04-04 VIRxSYS Corporation Vector packaging cell line
JP2006085744A (ja) 2004-09-14 2006-03-30 Matsushita Electric Ind Co Ltd 磁気記録再生装置及びそのテープスレッディング方法
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
EP2895203A4 (en) 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
EP3511413B1 (en) * 2014-07-25 2022-09-07 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
US20180127781A1 (en) 2015-01-21 2018-05-10 Fred Hutchinson Cancer Research Center Cocal envelope pseudotyped retroviral vector producer cells
EP3261651B1 (en) 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
WO2016147182A1 (en) * 2015-03-16 2016-09-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated peptides derived from the b7 ligand dimer interface and uses thereof
WO2017015427A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
CN108884460B (zh) 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3512540A1 (en) 2016-09-14 2019-07-24 Université Catholique de Louvain Modified vsv-g and vaccines thereof
CN118546256A (zh) 2016-12-13 2024-08-27 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
WO2018132508A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Methods and compositions relating to ex vivo culture and modulation of t cells
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN118634339B (zh) 2017-02-17 2025-07-01 珀杜研究基金会 用于细胞疗法的基于靶向性配体-有效负载的药物递送
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CN111479921B (zh) 2017-09-18 2024-08-02 埃克苏马生物技术公司 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
US20210093637A1 (en) 2017-12-07 2021-04-01 Dermavant Sciences GmbH Topical ointment formulations of pde-4 inhibitor and their use in treating skin conditions
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
WO2019157533A1 (en) 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
CA3108778A1 (en) 2018-08-06 2020-02-13 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
SG11202100616VA (en) 2018-08-07 2021-03-30 Purdue Research Foundation Rejuvenation of car t cell
WO2020106992A1 (en) 2018-11-21 2020-05-28 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
US12540336B2 (en) 2020-05-27 2026-02-03 The Medical College Of Wisconsin, Inc. Lentiviral vector transfer plasmid and methods of use
US11517814B2 (en) 2020-09-03 2022-12-06 Alan Chalmers Flavour system
JP2023551220A (ja) 2020-11-20 2023-12-07 ウモジャ バイオファーマ インコーポレイテッド 複数のポリヌクレオチドを送達するためのベクター系およびその使用法
MX2023008831A (es) 2021-01-27 2023-10-19 Umoja Biopharma Inc Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
AU2023265993A1 (en) 2022-05-06 2024-10-31 Umoja Biopharma, Inc. Viral particle with surface stimulating molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor

Also Published As

Publication number Publication date
JP7721436B2 (ja) 2025-08-12
CA3096458A1 (en) 2019-10-17
WO2019200056A2 (en) 2019-10-17
JP2024100972A (ja) 2024-07-26
IL277936A (en) 2020-11-30
SG11202009975TA (en) 2020-11-27
US20250122532A1 (en) 2025-04-17
AU2019252285A1 (en) 2020-10-29
IL327388A (en) 2026-05-01
AU2025237995A1 (en) 2025-10-16
US20250122533A1 (en) 2025-04-17
IL277936B1 (en) 2026-05-01
CN112262214A (zh) 2021-01-22
EP3775231A2 (en) 2021-02-17
JP2021520853A (ja) 2021-08-26
US20210147871A1 (en) 2021-05-20
WO2019200056A3 (en) 2020-01-09
BR112020020887A2 (pt) 2021-04-06
US12215337B2 (en) 2025-02-04
JP7855638B2 (ja) 2026-05-08

Similar Documents

Publication Publication Date Title
CN112262214A (zh) 病毒载体及包装细胞系
US12599678B2 (en) Methods and compositions for genomic integration
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
KR102729768B1 (ko) 트랜스제닉 선택 방법 및 조성물
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
AU2017323629B9 (en) PD-1 homing endonuclease variants, compositions, and methods of use
CN110770348B (zh) 嵌合抗原受体细胞的制备及其用途
US20250135031A1 (en) Single-vector gene construct comprising insulin and glucokinase genes
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
KR20220009980A (ko) 조절된 합성 유전자 발현 시스템
AU2018265261B2 (en) Optimized nucleic acid antibody constructs
KR20220130093A (ko) 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20240004253A (ko) 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법
KR20220041214A (ko) Il-1 수퍼패밀리의 사이토카인의 시공적 제한 활성으로 무장된 면역반응성 세포
CN115768890A (zh) 通过分子和物理启动对t细胞免疫疗法的热控制
CN115867295A (zh) 用于靶向hpv感染细胞的组合物和方法
KR20230041028A (ko) SARS-CoV-2 면역원성 조성물, 백신 및 방법
CN117120085A (zh) Sars-cov-2免疫原性组合物、疫苗和方法
HK40091239A (zh) 用於靶向hpv感染细胞的组合物和方法
CA2974235C (en) Single-vector gene construct comprising insulin and glucokinase genes
CN111801424A (zh) 双向chef1载体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)